Venus Remedies (BOM:526953) Stock Based Compensation: ₹0 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:526953 Venus Remedies Ltd BOM:526953
53 GF Score
Price ₹1,546.20
GF Value ₹523.32
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Venus Remedies Stock Based Compensation?

Venus Remedies BOM:526953 -3.88% 53 Stock Based Compensation is ₹0 Mil as of Jun. 2026. GuruFocus rates BOM:526953 with a GF Score™ of 53/100 and a GF Value™ of ₹523.32 (Significantly Overvalued). The stock has 2 warning signs investors should review.

Venus Remedies's Stock Based Compensation for the three months ended in Jun. 2026 was ₹0 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Jun. 2026 was ₹0 Mil.

Venus Remedies Stock Based Compensation Related Terms

Venus Remedies Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Venus Remedies's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Venus Remedies Stock Based Compensation Chart

Venus Remedies Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Venus Remedies Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
BOM:526953
53GF Score
Venus Remedies Ltd BOM:526953
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Venus Remedies Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.

What does a Stock Based Compensation of ₹0 Mil mean?
Venus Remedies (BOM:526953) has a Stock Based Compensation of ₹0 Mil as of Jun. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Venus Remedies and its competitors.
Is Venus Remedies' Stock Based Compensation too high?
Venus Remedies' current Stock Based Compensation is ₹0 Mil. Overall, Venus Remedies has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Venus Remedies' Stock Based Compensation compare to ZTS?
Venus Remedies' Stock Based Compensation of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Drug Manufacturers company?
A good Stock Based Compensation depends on the Drug Manufacturers industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Venus Remedies and its competitors. Venus Remedies's current Stock Based Compensation is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Venus Remedies stock overvalued right now?
Based on GuruFocus' analysis, Venus Remedies (BOM:526953) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹523.32, compared to a current price of ₹1,546.20 — trading 195.5% above its estimated fair value. The current Stock Based Compensation is ₹0 Mil. Venus Remedies' overall GF Score™ is 53/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Venus Remedies (BOM:526953), the current Stock Based Compensation is ₹0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Venus Remedies (BOM:526953) Overvalued in 2026?

Based on GuruFocus' analysis, Venus Remedies stock appears to be overvalued. The current stock price of ₹1,546.20 is trading 195.5% above its estimated GF Value™ of ₹523.32. GuruFocus considers Venus Remedies to be Significantly Overvalued.

Key valuation signals for BOM:526953:

  • Stock Based Compensation: ₹0 Mil
  • GF Value™: ₹523.32 vs. price of ₹1,546.20 (195.5% above fair value)
  • GF Score™: 53/100 with 2 warning signs

No single metric tells the full story. See the BOM:526953 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Venus Remedies Business Description

Other Exchanges VENUSREM:India
Address Plot 51-52, Industrial Area, Phase 1, Panchkula, HR, IND, 134113
Venus Remedies Ltd is an Indian drug manufacturer. It is engaged in manufacturing and trading pharmaceutical products. The company produces biologically active food supplements which include food supplements are natural complexes containing minerals, vitamins, dietary fibers, extracts of medicinal herbs, amino acids and others.
53GF Score

Get the complete analysis for BOM:526953

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,546.20
Price
₹523.32
GF Value